论文部分内容阅读
目的探讨不同抗体对原发性胆汁性肝硬化(PBC)患者的临床意义。方法随机选择2010年7月至2013年7月肝病患者245例,根据所患疾病种类不同,将患者分为PBC组、自身免疫性肝炎(AIH)组和肝病对照(LDC)组。采用ELISA法检测血清抗AMA-M2、抗SP100以及GP210抗体,采用western-blot法检测血清中抗SLA抗体,采用IIF法检测血清抗AMA。结果 PBC患者的AMA、AMA-M2、抗GP210、抗SLA的阳性率(93.21%、87.65%、25.93%、14.20%)均高于AIH患者(19.05%、7.14%、9.52%、0),差异有统计学意义(P均<0.05)。PBC患者的AMA、AMA-M2及抗GP210的阳性率(93.21%、87.65%、25.93%)均高于LDC患者(9.76%、2.44%、7.32%),差异有统计学意义(P均<0.05)。AMA阳性PBC患者的抗SP100、抗GP120及抗SLA阳性率(42.38%、30.46%、2.65%)低于AMA阴性PBC患者(63.64%、71.43%、0.09%),但差异无统计学意义(P均>0.05)。结论 AMA、AMA-MZ、抗GP210、抗SLA等抗体在PBC与其他肝病中的表达不同,AMA对PBC的诊断具有标志性意义。
Objective To investigate the clinical significance of different antibodies in patients with primary biliary cirrhosis (PBC). Methods A total of 245 liver cancer patients from July 2010 to July 2013 were randomly divided into PBC group, autoimmune hepatitis group (AIH) and control group (LDC) according to different types of diseases. Anti-AMA-M2, anti-SP100 and GP210 antibodies were detected by ELISA. Serum anti-SLA antibody was detected by western-blot and serum anti-AMA by IIF. Results The positive rates of AMA, AMA-M2, anti-GP210 and anti-SLA in PBC patients were significantly higher than those in AIH patients (19.05%, 7.14%, 9.52%, 0%, 93.21%, 87.65%, 25.93%, 14.20% There was statistical significance (all P <0.05). The positive rates of AMA, AMA-M2 and anti-GP210 in patients with PBC were significantly higher than those in patients with LDC (93.21%, 87.65%, 25.93%, 9.76%, 2.44%, 7.32%, respectively) ). The positive rates of anti-SP100, anti-GP120 and anti-SLA in AMA positive PBC patients were lower than those in AMA negative PBC patients (63.64%, 71.43%, 0.09%), but the difference was not statistically significant All> 0.05). Conclusion The expression of AMA, AMA-MZ, anti-GP210, anti-SLA and other antibodies is different between PBC and other liver diseases. AMA has landmark significance in the diagnosis of PBC.